Please ensure Javascript is enabled for purposes of website accessibility

Can Moderna and Pfizer Meet President Biden's Vaccine Goals?

By Adria Cimino - Updated Jan 29, 2021 at 8:32AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

These companies play a major role in the president's plan.

If the goal of President Joe Biden is met, at least 100 million doses of vaccine will be delivered into people's arms by his 100th day in office. In this Motley Fool Live video recorded on Jan. 22, 2021, healthcare and cannabis bureau chief Corinne Cardina and contributor Adria Cimino discuss whether Moderna (MRNA -3.21%) and Pfizer (PFE -1.83%) can make that happen.

Corinne Cardina: What are you watching to determine if you think the 100 million shots in the first 100 days is possible? And is there anything else that we know about the new U.S. vaccination plan under our new president?

Adria Cimino: Well, I think the 100 million doses, I think it's possible if we just look at what companies can produce. In an update earlier this month, for example, Moderna said that it plans on producing 100 million doses for the U.S. in the first quarter. Now, that would be before the president completes his first 100 days, so that's definitely within the time frame. Pfizer said that it will deliver 200 million doses by July 31. Now, we don't know the exact timing of when each batch will come along. But it would seem reasonable to think that between those two companies, we can get to that 100 million doses. But it also depends on logistics. There have been situations where some areas had doses, and they're just sitting around because people in those areas don't want to get vaccinated. Then in other areas where people really need doses, they don't have them. So that really can be an issue. So far, in Biden's vaccination plan, they've outlined several points. There's going to be, of course, more funding to states and towns to get this rolling. They're going to open up more vaccination centers. To start with, they're going to do about 100 vaccination centers in just a month. We can see what happens a month from now to see if that happens and the effects, how many people will actually get vaccinated, etc. They're also coordinating all the efforts on a federal level as far as all the federal agencies involved. They're going to know what each one is doing and they are going to be optimizing communication down to the local governments, down to the states and local governments. That's another important point because it seems that communication has really been an issue up until this point. Also, another important point is who is getting the vaccine? Now, right now it's really been older people. And Biden says that he wants to start encouraging vaccinations for those 65 plus -- so a little bit younger than the 75-plus crowd. Also, vaccination, it's been healthcare workers. But there are also other people who are in the front lines in the sense of they have a lot of contact with people -- like transport workers, or teachers, cashiers at the grocery stores. So those people would be the next on the list after the healthcare workers to get vaccinated. So, we'll see how that transpires down the road.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna, Inc. Stock Quote
Moderna, Inc.
$137.71 (-3.21%) $-4.57
Pfizer Inc. Stock Quote
Pfizer Inc.
$50.40 (-1.83%) $0.94

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/19/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.